Serotonergic modulation of dopamine measured with [11C]raclopride and PET in normal human subjects

American Journal of Psychiatry

Volumn 154, Issue 4, 1997, Pages 490-496

  Smith, Gwenn S ^a   Dewey, Stephen L ^b   Brodie, Jonathan D ^b   Logan, Jean ^b   Vitkun, Stephen A ^b   Simkowitz, Philip ^b   Schloesser, Ralf ^b   Alexoff, David A ^b   Hurley, Arlene ^b   Cooper, Thomas ^b   Volkow, Nora D ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; DOPAMINE; FENFLURAMINE; HOMOVANILLIC ACID; HYDROCORTISONE; NORFENFLURAMINE; PROLACTIN; RACLOPRIDE; SEROTONIN;

ADULT; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG LABELING; DRUG RECEPTOR BINDING; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; ISOTOPE LABELING; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RADIOISOTOPE DISTRIBUTION; SEROTONINERGIC SYSTEM;

EID: 0030913501     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.154.4.490     Document Type: Article

References (63)

1. Wong D, Wagner H, Tune L, Dannals R, Pearlson G, Links J, Tamminga C, Broussole E, Ravert H, Wilson A, Young J, Malat J, Williams J, O'Tuama L, Snyder S, Kuhar M, Gjedde A: Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986; 234:1558-1560
2. Farde L, Wiesel F-A, Stone-Elander S, Halldin C, Nordstrom A, Hall H, Sedvall G: D2 dopamine receptors in neuroleptic-naive schizophrenic patients. Arch Gen Psychiatry 1990; 47:213-219
3. 76Br]bromospiperone in untreated schizophrenic patients. Am J Psychiatry 1990; 147: 44-50
4. Andreasen NC, Carson R, Diksic M, Evans A, Farde L, Gjedde A, Hakim A, Lal S, Nair N, Sedvall G, Tune L, Wong D: Workshop on schizophrenia, PET, and dopamine D2 receptors in the human neostriatum. Schizophr Bull 1988; 14:471-484
5. Seeman P, Guan H, Niznik H: Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride. Synapse 1989; 3:96-97
6. 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 1993; 13:350-356
7. Volkow ND, Wang GJ, Fowler JS, Logan J, Schlyer D, Hitzemann R, Lieberman J, Angrist B, Pappas N, MacGregor R, Burr G, Cooper T, Wolf A: Imaging endogenous dopamine competition with [11C]raclopride in the human brain. Synapse 1994; 16:255-262
8. 18F-N-methylspirop-eridol binding in the baboon brain using positron emission tomography (PET). Synapse 1991; 7:324-327
9. Innis RB, Malison RT, al-Tikriti M, Hoffer PB, Sybirska EH, Seibyl JP, Zoghbi SS, Baldwin RM, Laruelle M, Smith EO, Charney D, Henninger G, Elsworth J, Roth R: Amphetamine-stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates. Synapse 1992; 10:177-184
10. Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue C-Y, Cooper TB, Brodie JD: Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 1989; 146:905-908
11. Coppens HJ, Slooff CJ, Paans AMJ, Wiegman T, Vaalburg W, Korf J: High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients. Biol Psychiatry 1991; 29:629-634
12. Wong D, Gjedde A, Wagner H, Dannals R, Douglass K, Links J, Kuhar M: Quantification of neuroreceptors in the living human brain, I: inhibition studies of receptor density and affinity. J Cereb Blood Flow Metab 1986; 6:147-153
13. Miller R: Time course of neuroleptic therapy for psychosis. Psychopharmacology (Berl) 1987; 92:405-415
14. 11C-raclopride and positron emission tomography. J Neurosci 1992; 12:3773-3780
15. Dewey SL, Smith G, Logan J, Simkowitz P, Brodie JD, Fowler JS, Volkow N, Wolf AP: Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography (PET) in normal human subjects. Proc Natl Acad Sci USA 1993; 90:11816-11820
16. Dewey S, Smith G, Logan J, Alexoff D, King P, Pappas N, Ashby C, Brodie J: The serotonergic-dopaminergic interaction in vivo with positron emission tomography (PET) and microdialysis. J Neurosci 1995; 15:821-829
17. Aghajanian GK, Bunney BS: Pre and post synaptic feedback mechanisms in central dopaminergic neurons, in Frontiers in Neurology and Neuroscience Research, vol 4. Edited by Seeman P, Brown GM. Toronto, University of Toronto, Neuroscience Institute, 1974, pp 11-24
18. de Belleroche J, Coutinho-Netto J, Bradford H: Dopamine inhibition of release of endogenous acetylcholine from corpus striatum and cerebral cortex in tissue slices and synaptosomes: a presynaptic response. J Neurochem 1982; 39:217-222
19. Waldmeier P, Delini-Stula A: Serotonin-dopamine interactions in the nigrostriatal system. Eur J Pharmacol 1979; 55:363-373
20. McBride P, Tierney H, DeMeo M, Chen J, Mann J: Effects of age and gender on CNS serotonergic responsivity in normal adults. Biol Psychiatry 1990; 27:1143-1155
21. 11C-raclopride in normal human subjects (abstract). J Nucl Med 1994; 35:85
22. Hollander E, DeCaria C, Nitescu A, Gully R, Suckow R, Cooper T, Gorman J, Klein D, Liebowitz M: Serotonergic function in obsessive-compulsive disorder. Arch Gen Psychiatry 1992; 49:21-28
23. Mann JJ, Malone KM, Diehl DJ, Perel J, Cooper TB, Mintun MA: Demonstration in vivo of reduced serotonin responsivity in the brain of untreated depressed patients. Am J Psychiatry 1996; 153:174-182; correction, 153:588
24. Mann JJ, Malone KM, Diehl DJ, Perel J, Cooper TB, Mintun MA: Demonstration in vivo of reduced serotonin responsivity in the brain of untreated depressed patients. Am J Psychiatry 1996; 153:174-182; correction, 153:588
25. Farde L, Hall H, Ehrin E, Sedvall G: Quantitative analysis of D2 receptor binding in the living human brain by PET. Science 1986; 231:258-261
26. Volkow ND, Fowler JS, Wang GJ, Dewey SL, Schlyer D, MacGregor R, Logan J, Alexoff D, Shea C, Hitzemann R, Angrist B, Wolf A: Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. J Nucl Med 1993; 34:609-613; correction, 34:838
27. Volkow ND, Fowler JS, Wang GJ, Dewey SL, Schlyer D, MacGregor R, Logan J, Alexoff D, Shea C, Hitzemann R, Angrist B, Wolf A: Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. J Nucl Med 1993; 34:609-613; correction, 34:838
28. Rendriein B, Dewey, SL, Schlyer D, Wolf A, Volkow N: Quantitation of the human basal ganglia with PET: a phantom study of the effect of contrast and axial positioning. IEEE Transactions on Med Imaging 1991; 10:216-222
29. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, MacGregor RR, Hitzemann R, Bendriem B, Gatley SJ, Christman D: Graphical analysis of reversible radioligand binding from time-activity measurements applied to (N-11C-methyl]-(-)-cocaine PET studies in human subjects. Cereb Blood Flow Metab 1990; 10:740-747
30. 11C-raclopride binding in the brain: model simulations and kinetic analysis of PET data. J Cereb Blood Flow Metab 1995; 14:995-1010
31. Farde L, Eriksson L, Blomquist G, Halldin C: Kinetic analysis of central [11C]-raclopride binding to D2-dopamine receptors studied by PET: a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 1989; 9:696-708
32. Seeman P, Niznik HB, Guan HC: Elevation of dopamine D2 receptors in schizophrenia is underestimated by radioactive raclopride (letter). Arch Gen Psychiatry 1990; 47:1170-1172
33. Flores CM, Hulihan-Giblin BA, Hornby PJ, Lumpkin MD, Kellar KJ: Partial characterization of a neurotransmitter pathway regulating the in vivo release of prolacrin. Neuroendocrinology 1992; 5:519-528
34. Hokfelt T, Farenkrug J, Tatemoto K, Mutt V, Werner S, Hulting AL, Terenius L, Chang KJ: The PHI (PHI-27)/corticotropin-releasing factor/enkephalin immunoreactive hypothalamic neuron: possible morphological basis for integrated control of prolactin, corricotropin and growth hormone secretion. Proc Natl Acad Sci USA 1983; 80:895-898
35. Hollander E, Cohen EJ, DeCaria C, Saoud JB, Stein DJ, Cooper TB, Islam NN, Liebowitz MR, Klein DF: Timing of neuroendocrine responses and effect of m-CPP and fenfluramine plasma levels in OCD. Biol Psychiatry 1993; 34:407-413
36. Hollander E, Stein D, Saoud J, DeCaria C, Cooper T, Islam N, Liebowitz M, Stanley M: Effects of fenfluramine on plasma homovanillic acid in healthy subjects. J Neural Transm 1992; 90:81-84
37. Schmidt C, Fadayel G, Sullivan C, Taylor V: 5HT-2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analog, 3,4-methylenedioxymethamphetamine. Eur J Pharmacol 1992; 223: 65-74
38. Azmitia EC, Segal M: An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J Comp Neurol 1978; 179:641-668
39. Parent A: A radioautographic study after intraventricular administration of [3H]5-hydroxytryptamine. Neuroscience 1981; 6:115-138
40. Dray A, Gonye T, Oakley N, Tanner T: Evidence for the existence of a raphe projection to the substantia nigra in the rat. Brain Res 1976; 113:45-57
41. Herve D, Pickel VM, Joh TH, Beaudet A: Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons. Brain Res 1987; 435: 71-83
42. Mennini T, Garattini S, Caccia S: Anorectic effect of fenfluramine isomers and metabolites. Psychopharmacology (Berl) 1985; 85:111-114
43. Burt D, Creese I, Snyder S: Properties of [3H]haloperidol and [3H]dopamine binding associated with calf brain membranes. Mol Pharmacol 1976; 12:800-812
44. Paul SM, Hulihan-Giblin B, Skolnick P: (+)-Amphetamine binding to rat hypothalamus: relation to anorexic potency of phenylethylamines. Science 1982; 218:487-490
45. Benloucif S, Keegan M, Galloway M: Serotonin-facilitated dopamine release in vivo: pharmacological characterization. J Pharmacol Exp Ther 1993; 265:373-377
46. Chen NH, Reith ME: Monoamine interactions measured by microdialysis in the ventral regmental area of rats treated systemically with (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin. J Neurochem 1995; 64:1585-1597
47. Yadid C, Pacak K, Kopin IJ, Goldstein DJ: Endogenous serotonin stimulates striatal dopamine release in conscious rats. J Pharmacol Exp Ther 1994; 270:1158-1165
48. Benloucif S, Galloway MP: Facilitation of dopamine release in vivo by serotonin agonists: studies with microdialysis. Eur J Pharmacol 1991; 200:1-8
49. Tiihonen J, Kuoppamaki M, Nagren K, Bergman J, Eronen E, Syvalahti E, Hietala J: Serotonergic modulation of striatal D2 dopamine receptor number in humans measured with positron emission tomography. Psychopharmacology (Bed) 1996; 126: 277-280
50. Chugani D, Ackermann R, Phelps M: In vivo [3H]spiperone binding: evidence for accumulation in corpus striatum agonist-mediated receptor internalization. J Cereb Blood Flow Metab 1988; 8:291-303
51. Ng G, Trogadis J, Stevens J, Bouvier M, O'Dowd B, George S: Agonist-induced desensitization of dopamine D1 receptor-stimulated adenyl cyclase activity is temporally and biochemically separated from D1 receptor internalization. Proc Natl Acad Sci USA 1995; 92:10157-10161
52. Holthoff VA, Koeppe RA, Frey KA, Paradise AH, Kuhl DE: Differentiation of radioligand delivery and binding in the brain: validation of a two-compartment model for [11C]-flumazenil. J Cereb Blood Flow Metab 1991; 11:745-752
53. Anjivel S, Malone K, Kessler D, Campbell C, Van Heertum R, Mann J: H215O PET imaging of regional cerebral blood flow in the brain after serotonin release induced by fenfluramine (abstract). Neuroimage 1996; 3:S471
54. 15O]-PET (abstract). Biol Psychiatry 1996; 39:516
55. Meltzer HY: Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Bed) 1989; 99(suppl):S18-S27
56. Deutsch AY, Moghaddam B, Innis RB, Krystal JH, Aghajanian GK, Bunney BS, Charney DS: Mechanisms of action of atypical antipsychotic drugs: implications for novel therapeutic strategies for schizophrenia. Schizophr Res 1991; 4:121-156
57. McDougle CJ, Goodman WK, Price LH: Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder. J Clin Psychiatry 1994; 55(March suppl):24-31
58. Brown A, Gershon S: Dopamine and depression. J Neural Transm Gen Sect 1993; 91:75-109
59. Gawin FH: Cocaine addiction: psychology and neurophysiology. Science 1991; 251:1580-1586; correction, 253:494
60. Gawin FH: Cocaine addiction: psychology and neurophysiology. Science 1991; 251:1580-1586; correction, 253:494
61. Ritz M, Cone E, Kuhar M: Cocaine inhibition of ligand binding at dopamine, norepinephrine and serotonin transporters: a structure-activity study. Life Sci 1990; 46:635-645
62. Potter WZ, Hsiao JK, Agren H: Neurotransmitter interactions as a target of drug action. Psychopharmacol Ser 1989; 7:40-51
63. Hsiao JK, Potter WZ, Agren H, Owen RR, Pickar D: Clinical investigation of monoamine neurotransmitter interactions. Psychopharmacology (Berl) 1993; 112(1, suppl):S76-S84